// App-Quantinova.ai

e20551 : Dynamic 18F-FDG Total body PET Imaging as a predictive marker of induction chemo-immunotherapy response in locally advanced non-small cell lung cancer.

Researchers

Presenter

  • Hui Liu

Principal Investigators

  • Bo Qiu

  • DaQuan Wang

  • Xu Zhang

  • Yin Zhou

  • QiWen Li

  • Chu Chu

  • FangJie Liu

  • NaiBin Chen

  • Nan Hu

  • XinLei Ai

  • JinYu Guo

  • Wei Fan

Medical Centers

  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

  • Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

  • Department of Clinical Trial Center, Sun Yat-sen University Cancer Center, Guangzhou, China

  • Molecular Imaging Business Unit, United-Imaging Healthcare, Shanghai, China

  • SuZhou TongDiao Company, Suzhou, China

  • GuangZhou, China

  • Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • 18F-fluorodeoxyglucose

Drug/Treatment

  • Docetaxel

  • Nivolumab

  • Cisplatin

  • Fludeoxyglucose (18F)

Outcome

  • N/A

Study Design

  • Randomized

  • Prospective

Phase

  • II

Study Id's

  • NCT04654234

  • NCT04085250

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved